Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk Mortality (b) 22% ICU admission 22% Hospitalization 3% Mortality (c) 8% Mortality (d) 16% ICU admission (b) 39% Hospitalization (b) -2% c19early.com/mf Ojeda-Fernández et al. Metformin for COVID-19 Prophylaxis Favors metformin Favors control
Ojeda-Fernández, 13,112 patient metformin prophylaxis PSM study: 16% lower mortality [p<0.0001], 22% lower ICU admission [p=0.01], and 3% lower hospitalization [p=0.11] https://c19p.org/ojedafernandez
copied to clipboard
Metformin use is associated with a decrease in risk of hospitalization and mortality in COVID-19 diabetic patients: a population-based study in Lombardy
Ojeda-Fernández et al., Diabetes, Obesity and Metabolism, doi:10.1111/dom.14648
10 Jan 2022    Source   PDF   Share   Tweet
Retrospective 31,966 COVID+ patients using anti-hyperglycemic drugs in Italy, showing lower mortality and ICU admission with metformin use.
risk of death, 16.2% lower, RR 0.84, p < 0.001, treatment 1,476 of 6,556 (22.5%), control 1,787 of 6,556 (27.3%), NNT 21, odds ratio converted to relative risk, propensity score matching.
risk of death, 22.1% lower, RR 0.78, p < 0.001, treatment 968 of 6,556 (14.8%), control 1,261 of 6,556 (19.2%), NNT 22, odds ratio converted to relative risk, in-hospital mortality, propensity score matching.
risk of ICU admission, 22.4% lower, RR 0.78, p = 0.01, treatment 166 of 6,556 (2.5%), control 212 of 6,556 (3.2%), NNT 143, odds ratio converted to relative risk, propensity score matching.
risk of hospitalization, 2.7% lower, RR 0.97, p = 0.11, treatment 3,551 of 6,556 (54.2%), control 3,670 of 6,556 (56.0%), NNT 55, odds ratio converted to relative risk, propensity score matching.
risk of death, 8.3% lower, RR 0.92, p = 0.06, treatment 793 of 3,297 (24.1%), control 876 of 3,297 (26.6%), NNT 40, odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
risk of death, 16.0% lower, RR 0.84, p = 0.003, treatment 512 of 3,297 (15.5%), control 618 of 3,297 (18.7%), NNT 31, odds ratio converted to relative risk, excluding patients previously treated with insulin, in-hospital mortality, propensity score matching.
risk of ICU admission, 39.2% lower, RR 0.61, p = 0.002, treatment 64 of 3,297 (1.9%), control 102 of 3,297 (3.1%), NNT 87, odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
risk of hospitalization, 2.2% higher, RR 1.02, p = 0.36, treatment 1,822 of 3,297 (55.3%), control 1,792 of 3,297 (54.4%), odds ratio converted to relative risk, excluding patients previously treated with insulin, propensity score matching.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Ojeda-Fernández et al., 10 Jan 2022, retrospective, Italy, peer-reviewed, 11 authors.
Contact: luisa.ojeda@marionegri.it.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit